Editorial (Thematic Issue: Antithrombotic Therapy: Current and Future Clinical Use)

Giancarlo Agnelli

doi:10.2174/157016111203140517190007

Related publications

Article2017

Efficacy and safety of triple <i>versus</i> dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis

Wengen Zhu, Linjuan Guo, Fadi Liu, Rong Wan, Yang Shen, Professor Gregory Lip, Kui Hong

Article2019

A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome, and percutaneous coronary intervention

Jakub Gumprecht, Magdalena Domek, Professor Gregory Lip

Article2022

Stroke Risk and Antithrombotic Treatment During Follow-up of Patients With Ischemic Stroke and Cortical Superficial Siderosis

Joan Martí‐Fàbregas, Pol Camps‐Renom, Jonathan G. Best, Anna Ramos‐Pachón, Marina Guasch‐Jiménez, Alejandro Martínez‐Domeño, Daniel Guisado‐Alonso, Beatriz Gómez‐Ansón, Gareth Ambler, Duncan Wilson, Keon‐Joo Lee, Jae‐Sung Lim, Hee‐Joon Bae, Masayuki Shiozawa, Masatoshi Koga, Ḱazunori Toyoda, Michael G. Hennerici, Hugues Chabriat, Éric Jouvent, Debbie Yuen Kwun Wong, Henry Ma, Kui Kai Lau, Young Dae Kim,

Article2003

Extended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism

Giancarlo Agnelli, Paolo Prandoni, Cecilia Becattini, Mauro Silingardi, Maria Rita Taliani, Maddalena Miccio, Davide Imberti, Renzo Poggio, Walter Ageno, Enrico Pogliani, Fernando Porro, Pietro Zonzin

Article2021

153 Anticoagulants and antiplatelets in COVID-19: impact on survival and thromboembolism development

Thomas Salmon, Mitchell Titley, Zaid Noori, Mark Crosby, Rajiv Sankaranarayanan